157 related articles for article (PubMed ID: 36275767)
1. Pulsed radiotherapy to mitigate high tumor burden and generate immune memory.
Sezen D; Barsoumian HB; He K; Hu Y; Wang Q; Abana CO; Puebla-Osorio N; Hsu EY; Wasley M; Masrorpour F; Wang J; Cortez MA; Welsh JW
Front Immunol; 2022; 13():984318. PubMed ID: 36275767
[TBL] [Abstract][Full Text] [Related]
2. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
Front Immunol; 2018; 9():2170. PubMed ID: 30294332
[TBL] [Abstract][Full Text] [Related]
3. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.
Barsoumian HB; Ramapriyan R; Younes AI; Caetano MS; Menon H; Comeaux NI; Cushman TR; Schoenhals JE; Cadena AP; Reilly TP; Chen D; Masrorpour F; Li A; Hong DS; Diab A; Nguyen QN; Glitza I; Ferrarotto R; Chun SG; Cortez MA; Welsh J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33106386
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
[TBL] [Abstract][Full Text] [Related]
5. NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model.
Barsoumian HB; He K; Hsu E; Bertolet G; Sezen D; Hu Y; Riad TS; Cortez MA; Welsh JW
Cancer Immunol Immunother; 2023 Sep; 72(9):3003-3012. PubMed ID: 37289257
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity.
Chen D; Barsoumian HB; Fischer G; Yang L; Verma V; Younes AI; Hu Y; Masropour F; Klein K; Vellano C; Marszalek J; Davies M; Cortez MA; Welsh J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581056
[TBL] [Abstract][Full Text] [Related]
8. NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model.
Barsoumian HB; He K; Hsu E; Bertolet G; Sezen D; Hu Y; Cortez MA; Welsh JW
Res Sq; 2023 Feb; ():. PubMed ID: 36824846
[TBL] [Abstract][Full Text] [Related]
9. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.
Belcaid Z; Phallen JA; Zeng J; See AP; Mathios D; Gottschalk C; Nicholas S; Kellett M; Ruzevick J; Jackson C; Albesiano E; Durham NM; Ye X; Tran PT; Tyler B; Wong JW; Brem H; Pardoll DM; Drake CG; Lim M
PLoS One; 2014; 9(7):e101764. PubMed ID: 25013914
[TBL] [Abstract][Full Text] [Related]
10. Radiation Therapy Modulates Tumor Physical Characteristics to Reduce Intratumoral Pressure and Enhance Intratumoral Drug Delivery and Retention.
Barsoumian HB; Sheth RA; Ramapriyan R; Hsu E; Gagea M; Crowley K; Sezen D; Williams M; Welsh JW
Adv Radiat Oncol; 2023; 8(2):101137. PubMed ID: 36632088
[TBL] [Abstract][Full Text] [Related]
11. Monitoring CD8a
Kristensen LK; Christensen C; Alfsen MZ; Cold S; Nielsen CH; Kjaer A
Mol Imaging Biol; 2020 Aug; 22(4):1021-1030. PubMed ID: 32086762
[TBL] [Abstract][Full Text] [Related]
12. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
13. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.
Carlson PM; Patel RB; Birstler J; Rodriquez M; Sun C; Erbe AK; Bates AM; Marsh I; Grudzinski J; Hernandez R; Pieper AA; Feils AS; Rakhmilevich AL; Weichert JP; Bednarz BP; Sondel PM; Morris ZS
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639155
[TBL] [Abstract][Full Text] [Related]
14. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
Niknam S; Barsoumian HB; Schoenhals JE; Jackson HL; Yanamandra N; Caetano MS; Li A; Younes AI; Cadena A; Cushman TR; Chang JY; Nguyen QN; Gomez DR; Diab A; Heymach JV; Hwu P; Cortez MA; Welsh JW
Clin Cancer Res; 2018 Nov; 24(22):5735-5743. PubMed ID: 29784675
[No Abstract] [Full Text] [Related]
15. Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.
Rudqvist NP; Pilones KA; Lhuillier C; Wennerberg E; Sidhom JW; Emerson RO; Robins HS; Schneck J; Formenti SC; Demaria S
Cancer Immunol Res; 2018 Feb; 6(2):139-150. PubMed ID: 29180535
[TBL] [Abstract][Full Text] [Related]
16. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma.
Kim KJ; Lee HW; Seong J
J Gastroenterol Hepatol; 2021 May; 36(5):1357-1365. PubMed ID: 33217056
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
19. A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.
Li M; Xing S; Zhang H; Shang S; Li X; Ren B; Li G; Chang X; Li Y; Li W
Oncol Rep; 2016 Mar; 35(3):1329-39. PubMed ID: 26752000
[TBL] [Abstract][Full Text] [Related]
20. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]